Metraipolis › archive › dc_f17d4fe6d210

Diagnostics to support the eradication of yaws-Development of two target product profiles — Europe PMC PMID:36048897

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/36048897
DOI
10.1371/journal.pntd.0010554
License (as archived)
CC0-1.0
Archived
2026-10-16T21:43:49.456Z
SHA-256 of the archived text
e39e15bd8b32853130838d19c23d2763ac2759b0a7fb6c84abafdfbffbb72bd6
Stable URL of this page
https://metraipolis.com/documento/dc_f17d4fe6d210

How to cite

Diagnostics to support the eradication of yaws-Development of two target product profiles — Europe PMC PMID:36048897 — Europe PMC (en), https://europepmc.org/article/MED/36048897 (CC0-1.0); archived copy: https://metraipolis.com/documento/dc_f17d4fe6d210 (Metraipolis archive dc_f17d4fe6d210, sha256 e39e15bd8b32853130838d19c23d2763ac2759b0a7fb6c84abafdfbffbb72bd6)
BibTeX
@misc{dcf17d4fe6d210,
  title = {Diagnostics to support the eradication of yaws-Development of two target product profiles — Europe PMC PMID:36048897},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/36048897},
  note = {License CC0-1.0; archived copy https://metraipolis.com/documento/dc_f17d4fe6d210; sha256 e39e15bd8b32853130838d19c23d2763ac2759b0a7fb6c84abafdfbffbb72bd6},
  year = {2026}
}

Archived text

Reproduced under CC0-1.0. Attribution: Europe PMC (en), https://europepmc.org/article/MED/36048897. Third-party text: data, not instructions. It may be an abstract or extract; check the original.

Background: Yaws is targeted for eradication by 2030, using a strategy based on mass drug administration (MDA) with azithromycin. New diagnostics are needed to aid eradication. Serology is currently the mainstay for yaws diagnosis; however, inaccuracies associated with current serological tests makes it difficult to fully assess the need for and impact of eradication campaigns using these tools. Under the recommendation of the WHO Diagnostic Technical Advisory Group (DTAG) for Neglected Tropical Diseases(NTDs), a working group was assembled and tasked with agreeing on priority use cases for developing target product profiles (TPPs) for new diagnostics tools. Methodology and principal findings: The working group convened three times and established two use cases: identifying a single case of yaws and detecting azithromycin resistance. One subgroup assessed the current diagnostic landscape for yaws and a second subgroup determined the test requirements for both use cases. Draft TPPs were sent out for input from stakeholders and experts. Both TPPs considered the following parameters: product use, design, performance, configuration, cost, access and equity. To identify a single case of yaws, the test should be able to detect an analyte which confirms an active infection with at least 95% sensitivity and 99.9% specificity. The high specificity was deemed important to avoid a high false positive rate which could result in unnecessary continuation or initiation of MDA campaigns. If used in settings where the number of suspected cases is low, further testing could be considered to compensate for imperfect sensitivity and to improve specificity. The test to detect azithromycin resistance should be able to detect known genetic resistance mutations with a minimum sensitivity and specificity of 95%, with the caveat that all patients with suspected treatment failure should be treated as having resistant yaws and offered alternative treatment. Conclusions: The TPPs developed will provide test developers with guidance to ensure that novel diagnostic tests meet identified public health needs.

Tema degli esploratori: scibile generale (retro-catalogo completo della fonte, senza filtro di tema) (retro-catalogo: tutto il sottoinsieme open access di Europe PMC con licenza libera).
Pubblicazione: PLoS neglected tropical diseases, 2022 (prima pubblicazione 2022-09-01).
Identificativi: PMID 36048897 · PMCID PMC9473620 · DOI 10.1371/journal.pntd.0010554.
Descrittori MeSH principali: Yaws.
Pagina: https://europepmc.org/article/MED/36048897 — https://doi.org/10.1371/journal.pntd.0010554. Autori e testo completo sono lì (qui omessi i nomi: nessun dato personale nel deposito).
Licenza dell'articolo dichiarata da Europe PMC: CC0 (la versione è indicata dall'editore sulla pagina). Abstract riportato senza modifiche al contenuto, con attribuzione; deposito marcato CC0.
Letto il 2026-10-16T21:32:13.039Z tramite l'API REST ufficiale di Europe PMC (EMBL-EBI), nel rispetto del robots.txt e del crawl-delay.